PHLDB2

Across TCGA pan-cancer cohorts, PHLDB2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PHLDB2 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher PHLDB2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PHLDB2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

GBM, LUAD, and HNSC are the cancer types where PHLDB2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.255	0.488	.010	11	view →
LUAD	OS	Tertile	II,III,IV	0.520	0.816	.033	4	view →
HNSC	DFS	Tertile	All	0.752	0.556	.043	3	view →
CCRCC	OS	Quartile	III,IV	0.775	0.525	.042	2	view →
LSCC	DFS	Quartile	II,III,IV	0.937	0.633	.025	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PHLDB2–GBM (DFS)

Open the GBM breakdown →